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Bacteria Producing Helicobacter pylori Urease B
Subunit Partially Protects against Challenge
with Helicobacter felis
Blaise Corthe´sy,1 Soledad Boris,3,a Patrick Isler,2 Corinne Grangette,3 and Annick Mercenier3,a
1R&D Laboratory of the Division of Immunology and Allergy and 2Division of Gastroenterology, Centre Hospitalier Universitaire Vaudois, Lausanne,
Switzerland; 3Laboratory of Bacteriology of Ecosystems, Institut Pasteur de Lille, Lille, France
Background. The development of an efficacious vaccine against infection with Helicobacter pylori, the causative
agent of chronic gastritis, peptic ulcer disease, and gastric adenocarcinoma, remains a challenge. Since the use of
mucosal adjuvants is limited in human application, we have evaluated the potential of recombinant Lactobacillus
strains producing H. pylori urease B (UreB) subunit to deliver this antigen to the gastrointestinal tract.
Methods. Mice were injected orally 3 times with a triple dose of recombinant Lactobacillus plantarum
NCIMB8826, the recombinant isogenic cell-wall mutant (alr MD007 strain) expressing UreB, or a mixture of
recombinant UreB and cholera toxin (rUreB/CT) as a control. Urease-specific seric immunoglobulin (Ig) G and
IgA were measured by use of an enzyme-linked immunosorbent assay. After challenge with Helicobacter felis,
stomach infection was examined by use of the rapid urease test and by polymerase chain reaction detection of
Helicobacter genomic DNA.
Results. Intragastric immunization with both recombinant Lactobacillus strains and rUreB/CT elicited UreB-
specific antibodies. After challenge, reduction of H. felis load in the stomachs of mice was observed only after
immunization with the recombinant mutant strain MD007 or with rUreB/CT.
Conclusions. This is the first report of successful induction of partial protection against H. felis with a mucosal
prime-boost regimen in which recombinant Lactobacillus strains were used as antigen-delivery vehicles.
Helicobacter pylori is recognized as a human-specific gas-
tric pathogen that colonizes the stomachs of at least
half of the world’s population. Most infected individ-
uals are asymptomatic, although, for a significant num-
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ber, infection is associated with the development of
duodenal and gastric ulcers and gastric cancers [1]. That
natural immunity appears to be inadequate for clearing
the infection questions the feasibility of producing an
effective H. pylori vaccine [2]. Intragastric immuniza-
tion with H. pylori virulence factors in combination
with mucosal adjuvants, such as bacterial toxins, has
been proven to eradicate the pathogen [3–6] and to
prevent reinfection [7] in animal models. Notably, the
urease B (UreB) subunit of urease, which exhibits sub-
stantial cross-reactivity between Helicobacter strains and
species, has been extensively used as a protecting an-
tigen in combination with cholera toxin (CT) or Esch-
erichia coli heat-labile toxin [8, 9]. However, toxin-
based adjuvants lead to numerous adverse effects, which
preclude their applicability in humans [10]. Other ap-
proaches based on the use of attenuated Salmonella
strains [11, 12] or nanoparticles [13] triggered a val-
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uable degree of protection in mouse models, yet efficacy in
humans remains to be established. A key issue is the nature of
the immune response required to eliminate Helicobacter infec-
tion; ambiguities remain with regard to the dispensability of
antibody responses [14–16]. Antigen delivery should be de-
signed to stimulate mucosal immunity with, possibly, a Th2
bias in the absence of proinflammatory adverse effects, because
the early induction of a Th1 response causes damage in the
host and is ineffective at clearing infection in humans [17].
Prevention of attachment of the pathogen and subsequent
colonization at mucosal surfaces is best achieved when im-
munity is triggered after local stimulation. Different delivery
systems satisfying this requirement are currently under devel-
opment, with various avenues being explored for oral admin-
istration [18]. One such delivery system is based on live bac-
terial vectors, including nonpathogenic, noninvasive lactic acid
bacteria (LAB) strains (which are generally recognized as safe)
[19]. These carriers do not induce pronounced proinflamma-
tory responses [19, 20], which renders them best suited for
immunocompromised subjects, infants, and elderly individ-
uals [21]. In the present study, the Lactobacillus plantarum
NCIMB8826 strain was chosen for its capacity to resist passage
through the stomach and to persist in mice for up to 1 week
[22, 23]. Further, intragastric immunization using the recom-
binant strain expressing the potent immunogen tetanus tox-
in fragment C (TTFC) elicited both humoral and local pro-
tective antibody responses [24]. A mutant of L. plantarum
NCIMB8826 (alr MD007 strain) affected in its cell-wall com-
position as a result of the inactivation of the alanine racemase
(alr) gene [25] led to substantially enhanced immune responses
in the same TTFC model [26].
In this article, we assess the potential of both the wild-type
(wt) L. plantarum NCIMB8826 strain and the isogenic alr
MD007 strain producing H. pylori UreB as oral delivery vehicles
in a mouse model of H. felis infection. In prophylactically
treated mice, although both recombinant strains induced seric
UreB–specific antibody to levels similar to those elicited by
intragastric administration of recombinant UreB (rUreB)/CT,
the recombinant alr MD007 mutant was more potent at re-
ducing H. felis load than was the recombinant NCIMB8826
strain, as assessed by rapid urease test (RUT) and polymerase
chain reaction (PCR) screening. We conclude that the recom-
binant alr MD007 mutant is a valid vaccine vehicle to trigger
partial mucosal protection against H. felis used as a model gas-
tric pathogen.
MATERIALS AND METHODS
Construction of recombinant Lactobacillus strains. The 1700-
bp DNA fragment coding for UreB was amplified from the
pTCP3 plasmid by PCR [27] and cloned into SfrI-restricted
PCRscript vector (Stratagene), yielding pMEC120. The ureB
insert was next cloned into a derivative of pGIT032 [28] pre-
viously cleaved with NcoI and PvuII, yielding pMEC142 car-
rying the UreB-coding sequence under the control of the strong
constitutive l-lactate dehydrogenase promoter of L. plantarum.
Cloning intermediates were amplified in E. coli XL1Blue and
JM110, and the final construct (pMEC142) was introduced in
the E. coli strain M15. The pTG2247 plasmid [29] devoid of
urease-coding sequence was used as a control. Transformation
of pMEC142 plasmids into the L. plantarum NCIMB8826 strain
[29] and the alr MD007 mutant [25] was performed as de-
scribed by Josson et al. [30]. Production of UreB from the
pMEC142 construct was targeted to the bacterial cytoplasm.
Bacterial strains and growth conditions. L. plantarum
NCIMB8826 carrying pMEC142 (referred to as “8826/pMEC142”)
was grown at 37C in Man-Rogosa-Sharpe (MRS) broth (Dif-
co) supplemented with 5 mg/mL erythromycin. L. plantarum
NCIMB8826 carrying pTG2247 (referred to as “8826/pTG2247”)
was grown at 37C in MRS broth supplemented with 10 mg/
mL chloramphenicol. Cultures were grown to midexponential
phase (OD600 of 0.8–1.0), and bacteria were collected by cen-
trifugation (4000 g for 10 min), washed twice in PBS, and
resuspended at a final concentration of cfu/mL in PBS101 10
or gavage buffer (0.5% casein hydrolysate, 0.2 mol/L sodi-
um bicarbonate, and 0.5% glucose in PBS) for systemic or
intragastric immunization, respectively. The L. plantarum alr
MD007 mutant carrying pMEC142 (referred to as “MD007/
pMEC142”) was grown in MRS broth supplemented with 5
mg/mL erythromycin and 200 mg/mL D-alanine (D-Ala). Before
administration in mice, bacteria were starved for 4 h in the
absence of D-Ala, which does not lead to growth arrest or a
drop in viability [25]. Bacterial counts and resuspension were
performed as they were for 8826/pMEC142 and 8826/pTG2247.
E. coli strains were grown in Luria broth medium contain-
ing 100 mg/mL ampicillin at 37C under aeration. H. felis strain
ATCC 49179 was grown biphasically under microaerophilic
conditions at 37C, as described elsewhere [7].
Structural stability of the recombinant pMEC142 plasmid
in vitro. The 8826/pMEC142 strain was subcultured in se-
lective medium (MRS broth supplemented with 5 mg/mL eryth-
romycin). Ten successive cultures were performed by inocu-
lating 10 mL of fresh medium with 10 mL of the previous culture
every 24 h. Bacterial cells from cultures after 1, 5, and 10 pas-
sages were recovered and subjected to immunoblot analysis, as
described below. Plasmid pMEC142 was extracted from 2 in-
dependent colonies originating from passages 1, 5, or 10 and
served as a source of DNA for PCR and restriction analyses.
Western-blot assay. A total of recombinant bacteria81 10
(L. plantarum and E. coli) were lysed in reducing SDS-con-
taining buffer [31], separated by PAGE, and transferred onto
blotting membrane. After blocking for 1 h at 37C with PBS–
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Figure 1. Experimental setting for the prophylactic immunization of mice with recombinant Lactobacillus strains (upper part of the time line).
Priming and boosting injections were given at 3-week intervals. Control immunization was performed with recombinant urease B (rUreB) combined
with cholera toxin (CT) (lower part of the time line). UreB-specific antibodies were measured before immunization, after the second booster injection,
and after infection with Helicobacter felis at the time of killing of the mice. Presence of H. felis was examined by rapid urease test and real-time
polymerase chain reaction (RT-PCR) analyses of genomic DNA recovered from the stomachs of mice.
0.5% Tween 20 (PBS-T) containing 5% skimmed milk (SM),
detection of UreB was performed with specific monoclonal
antibody (1:500 dilution) [32] in conjunction with alkaline
phosphatase–conjugated rabbit anti–mouse IgG diluted 1:3000.
UreB was detected by use of rabbit antiserum (1:2000 dilution
in PBS-T containing 0.5% SM) [33], followed by horseradish
peroxidase (HRP)–conjugated goat anti–rabbit IgG (1:3000 di-
lution; Sigma).
Antigens. Recombinant UreB was obtained from E. coli, as
described elsewhere [5]. CT was purchased from Calbiochem.
Recombinant urease holoenzyme [7] or H. felis lysate was used
to determine specific seric IgG and IgA antibody titers by use
of an ELISA.
Systemic immunization. Eight-week-old female C57/Bl6
mice (Charles River Laboratories) were immunized by sub-
cutaneous (sc) administration of UreB-producing L. plantarum
8826/pMEC142 or E. coli M15/pMEC142. Mice (groups of 5)
received a single dose of cfu of each recombinant strain91 10
3 times, at 2-week intervals. Serum samples were recovered 7
days after the first and second booster injections.
Intragastric immunization and infection with H. felis.
Specific pathogen–free female BALB/c mice were housed in
microisolator cages, with free access to water and chow, as
approved by the local veterinary office. Groups of 10 mice were
injected intragastrically with cfu of recombinant Lac-91 10
tobacillus strains in 200 mL of gavage buffer 3 times for 3 con-
secutive days, at 3-week intervals (figure 1). Control mice were
injected with MRS broth alone or with rUreB/CT (50 mg/10
mg). Feces were collected to examine the presence of recom-
binant strains and their capacity to maintain production of
UreB. Twelve days after the last immunization, mice were in-
fected with freshly cultured H. felis by orogastric in-75 10
tubation under light anesthesia with isofluran (Baxter); this
guarantees 190% infection in unvaccinated mice [7]. Mice were
killed 2 weeks later, and stomachs were collected to examine
the degree of protection.
Measurement of serum antibodies. Maxisorp immuno-
plates (Nunc) were coated overnight at 4C with 0.5 mg of re-
combinant urease holoenzyme or 1 mg of H. felis lysate [34].
Mouse serum dilutions in Tris-buffered saline–T:0.5% SM were
incubated for 2 h at 37C. Urease-specific antibodies were de-
tected by use of either rabbit anti-IgG or goat anti-IgA (a-
chain specific) coupled with HRP (Sigma). Antibody dilutions
yielding absorbance values 2-fold higher than those yielded by
the preimmune serum were used to establish end-point titers.
Quantitative analysis of H. felis colonization. In method
1, the presence of H. felis in gastric tissue was assessed by use
of RUT (Jatrox-test; Procter & Gamble) [5]. The cut-off value
of RUT used to discriminate between infection and cure cor-
responded to the mean  2 SDs of the absorbance values
obtained with gastric tissues from naive mice. In method 2, 20
mg of stomach sample was cut into small pieces and homog-
enized in 180 mL of ATL buffer (Qiagen). After digestion with
1.5 mg/mL proteinase K for 30 min at 55C, 200 mL of AL
buffer (Qiagen) was added. The mixture was incubated for 10
min at 70C, 200 mL of 100% ethanol was added, and the
precipitate was cleared by centrifugation. The lysate was ex-
tracted twice with phenol-chloroform (1:1), and the DNA was
precipitated with 2.5 vol of ethanol before washing, drying, and
final resuspension in water. A specific pair of primers for H.
felis flaB (5′-TTCGATTGGTCCTACAGGCTCAGA-3′ [sense]
and 5′-TTCTTGTTGATGACATTGACCAACGCA-3′ [anti-
sense]) was combined with 1 mg of DNA template, and real-
time PCR amplification was performed as described by Stoicov
et al. [35]. Standards were obtained accordingly, allowing for
quantification of bacteria per microgram of gastric tissue [35].
Cytokine/chemokine expression in stomach samples. Total
stomach RNA was extracted and reverse transcribed, as de-
scribed elsewhere [36]. The cDNA was amplified by PCR with
primers specific for tumor necrosis factor (TNF)–a, monocyte
chemoattractant protein (MCP)–1, and RANTES. The samples
were subjected to 40 PCR cycles, consisting of denaturation
1444 • JID 2005:192 (15 October) • Corthe´sy et al.
Figure 2. Production of urease B (UreB) and plasmid structural stabil-
ity in the Lactobacillus plantarum NCIMB8826 strain. Production of UreB
was assessed by use of whole bacterial lysates, separation by SDS-PAGE,
and immunodetection. Lane 1, Five micrograms of purified H. pylori recombi-
nant UreB; lane 2, Escherichia coli strain M15 carrying vector pMEC142;
lane 3, L. plantarum 8826/pMEC142; lanes 4–9, UreB production by 8826/
pMEC142 (2 independent clones) assayed after 1, 5, and 10 passages (Ps),
respectively. The asterisk indicates UreB-specific signals.
Figure 3. Capacity of Lactobacillus plantarum 8826/pMEC142 to de-
liver urease B (UreB) in vivo. Mice were injected subcutaneously, and
serum IgG antibody titers specific for UreB were established by end-point
dilutions (reciprocal of the last dilution giving an optical density higher
than 2 times the background) after the first and second booster injections.
Negative and positive controls included PBS and Escherichia coli carrying
vector pMEC142, respectively.
(for 1 min at 94C), annealing (for 1 min at 56C–60C), and
extension (for 1 min at 72C). Visualization and quantification
of PCR products were performed as described elsewhere [37],
and results were expressed as ratios to the groups given gavage
buffer by use of glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), for standardization between samples.
Statistical analysis. Antibody titers and H. felis copy num-
bers are reported as means  SDs and were compared by use
of Student’s t test. RUT values were compared by use of the
Mann-Whitney U test. was considered to be statisticallyP ! .05
significant for differences between groups.
RESULTS
UreB production level and structural stability of the L. plan-
tarum strains in vitro. We first evaluated the amount of UreB
produced in vitro by the 8826/pMEC142 strain and compared
it with that produced by positive controls consisting of 5 mg of
purified rUreB and that produced from the pMEC142 plasmid
in E. coli strain M15. By immunoblot analysis, a band of similar
intensity was observed in all 3 lanes (figure 2, lanes 1–3), dem-
onstrating that full-length UreB can be produced intracellularly
in the NCIMB8826 strain with a yield close to that produced in
E. coli (5 mg/ bacteria). As illustrated in figure 2, similar81 10
levels of UreB were observed by immunodetection along a time
course covering 10 successive culture passages in selective me-
dium, arguing for structural stability of the expression plasmid.
PCR analysis of plasmid pMEC142 extracted from 2 independent
clones confirmed that the plasmid was not rearranged during
subculturing of the strain (data not shown). The segregational
stability of the recombinant strains was examined by inoculating
them at a 1:400 dilution in nonselective medium. After ∼25
generations, 120% of the cells reaching late stationary phase
retained the plasmid (data not shown).
Evaluation of the immunogenicity of the recombinant 8826/
pMEC142 strain. Before conducting intragastric immuniza-
tion, we first examined whether the amount of UreB produced
by the model strain 8826/pMEC142 was sufficient to trigger a
measurable antibody response when administered sc to mice.
Injection of cfu resulted in UreB-specific IgG titers well91 10
above background levels obtained with sham-injected mice (fig-
ure 3). Specific antibody titers were not improved by the con-
comitant addition of alum as an adjuvant (data not shown).
Mice injected with recombinant E. coli producing UreB exhib-
ited 5-fold higher titers (figure 3), which is consistent with the
higher intrinsic adjuvanticity of this expression host.
Intragastric immunization with recombinant L. plantarum
strains and IgA and IgG responses. As outlined in figure 1,
intragastric administration of recombinant L. plantarum strains
was performed 3 times on 3 consecutive days. For practical
reasons, priming and boosting injections were done with bac-
teria from the same culture batch kept in gavage buffer for 2
days at 4C. No viability loss was observed for the recombinant
wt strains after 48 h of storage, yet viable counts were reduced
by 1 log for the MD007 strain at 48 h (data not shown). Notably,
the relative abundance of UreB in bacterial lysates did not de-
crease during storage and was equivalent to 10 mg of rUreB
(figure 4A). Previous experiments have shown that the survival
capacities of the NCIMB8826 and MD007 strains in the mouse
Recombinant LAB Protect against H. pylori Infection • JID 2005:192 (15 October) • 1445
Figure 4. A, Western-blot analysis of urease B (UreB) production by the Lactobacillus plantarum 8826/pMEC142 and MD007/pMEC142 strains. A
total of 100 mg of bacterial lysate was loaded per lane; 5 and 10 mg of purified recombinant UreB (rUreB) were loaded alongside to permit quantification.
Days 1, 2, and 3 indicate the UreB content of cell lysates from bacteria administered at days 1, 2, and 3 of the first booster injection. Molecular
weight markers are shown on the left side of the panel. B, Western-blot analysis of UreB production by 8826/pMEC142 and MD007/pMEC142 recovered
from mouse feces, performed as described in panel A (1 representative colony of 10). C, Determination of anti-UreB–specific IgA and IgG responses
after immunization. Serum titers were established by end-point dilutions after immunization (gray bars) and after infection with Helicobacter felis (black
bars). Data were averaged from 5 mice randomly picked per group and are expressed as means  SDs. * , by comparison with gavage buffer;P .01
** , by comparison with gavage buffer. 8826/pMEC142, L. plantarum NCIMB8826 producing UreB; 8826/pTG2247, recombinant L. plantarumP .001
NCIMB8826 not producing UreB; gavage buffer, negative control; MD007/pMEC142, alr MD007 mutant producing UreB; rUreB/CT, a mixture of rUreB
and cholera toxin serving as positive control.
gastrointestinal (GI) tract were equivalent (data not shown).
We further verified that colonies recovered from feces contin-
ued to produce UreB (figure 4B).
The production of specific seric IgA and IgG antibodies in-
dicated that mucosal delivery of the antigen was successful [38].
We thus evaluated production of these classes of antibodies to
assess whether UreB delivered by L. plantarum was efficiently
recognized in the GI tract. Mice that received the 8826/pMEC142
or MD007/pMEC142 strain or rUreB/CT intragastrically pro-
duced significant ( ) levels of UreB-specific IgA,P ! .01–.001
compared with preimmune mice (figure 4C, gray bars). Infec-
tion with H. felis did not induce production of more antibody
during the 2 weeks preceding euthanasia of the mice (figure
4C, black bars). Levels of specific IgA barely exceeded back-
ground levels in groups receiving the 8826/pTG2247 strain or
gavage buffer. A similar response pattern was seen when pro-
duction of UreB-specific IgG was assessed. We thus explored
whether the onset of immune responses by recombinant LAB
would lead to protection in a mouse model of H. felis infection.
Protection against H. felis infection in mice. Protection
was evaluated 2 weeks after infection of immunized mice with
H. felis, by use of RUT. The stomachs of mice given the L.
plantarum MD007/pMEC142 mutant strain showed slower color
development, compared with the stomachs of mice given the wt
8826/pMEC142 strain. This correlated with end-point values
measured at 3 h, which showed a significant difference (P !
) in the case of only MD007/pMEC142 (figure 5A). No re-.05
duction in H. felis load in the stomachs of mice was observed
upon intragastric administration of the 8826/pTG2247 control
strain or gavage buffer. As a validation of the immunization and
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Figure 5. Evaluation of protection against Helicobacter felis infection.
A, Collection of half stomachs from mice, which were assayed by use
of the rapid urease test, 2 weeks after infection, as described in Material
and Methods. The presence of H. felis in gastric tissues was assessed
by urease activity measured photometrically at an optical density (OD)
of 550 nm after a 3-h incubation. Abbreviations for lane content are the
same as those given in figure 4B. Statistical treatment of the data was
conducted by use of the Mann-Whitney U test ( ). B, Quantitativenp 9
polymerase chain reaction for H. felis infection, reported as the no. of
bacteria (as a function of gene copy no.) per micrograms of gastric tissue.
Results are means  SDs ( ).np 6
challenge setting, the highest degree of protection ( ) wasP ! .02
achieved with rUreB/CT, as described elsewhere (figure 5A) [5].
To more finely monitor H. felis load, we performed real-time
PCR on genomic DNA isolated from the stomachs of experi-
mentally infected mice. In this assay, changes in the number
of H. felis are expressed as a function of gene copy number,
on the basis of the premise that 2 fg of H. felis chromosomal
DNA is equivalent to 1 copy of H. felis genome [35]. No sig-
nificant modification of the bacterial loads was observed in the
groups that received gavage buffer or 8826/pTG2247 (figure
5B). A slight decrease ( ) in H. felis load was observedPp .07
when 8826/pMEC142 was used, but a significant decrease (P
p .011) was seen in mice immunized with MD007/pMEC142
(figure 5B). H. felis load was lowest in mice vaccinated with
rUreB/CT and was not detected in mice not specifically infected
(data not shown).
In infection studies, local inflammation in the stomach an-
trum is accompanied by production of MCP-1, RANTES, and
TNF-a [39]. Since quantitative levels of protein cannot be de-
termined from stomach samples, we evaluated possible changes
in the gastric mucosal production of these chemokines/cytokine
by use of real-time PCR (figure 6A). Although immunization
of mice with 8826/pTG2247 or 8826/pMEC142 yielded mRNA
levels comparable to those found in mice given gavage buffer,
a decrease in expression of MCP-1, RANTES, and TNF-a was
measured in mice immunized with MD007/pMEC142 or rUreB/
CT (figure 6B). These findings are consistent with the fact that
prevention of attachment or clearance of Helicobacter species
reduces local inflammation mediated by chemokines released
by epithelial cells upon contact with the bacterium [33]. To-
gether, these data demonstrate that partial protection against
challenge with H. felis in mice can be obtained by use of Lac-
tobacillus strains as live vaccine vehicles.
DISCUSSION
The rationale behind the development of dietary LAB as a live
mucosal delivery system is that they have been used from time
immemorial in the preparation of fermented foods and feeds
and, thus, have been consumed worldwide by humans and
animals. Moreover, specific LAB strains have been shown to
exert beneficial health—that is, probiotic—effects [40, 41] and
to be particularly adapted to immunization by the oral route,
since they are quite acid resistant. One such strain is L. plan-
tarum NCIMB8826, an isolate of human origin that has been
shown to establish itself in the mouse intestine and persist for
∼1 week [22], which supports the notion that L. plantarum is
able to replicate in the mouse intestine. This strain has also
been reported to present appropriate pharmacokinetic prop-
erties for use in humans [23].
In the present study, we investigated whether the intrinsic
characteristics of L. plantarum NCIMB8826 would turn it into
an adequate vector to deliver the H. pylori UreB antigen pro-
phylactically via the intragastric route. The NCIMB8826 strain
was previously shown to behave as a well-performing vaccine
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Figure 6. A, Sequences of primers used for real-time polymerase chain reaction (RT-PCR) amplification: tumor necrosis factor (TNF)–a, monocyte
chemoattractant protein (MCP)–1, RANTES, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). B, Relative mRNA expression, determined by
RT-PCR, in the stomachs of immunized mice and in those of control mice. Ratios were obtained by dividing the mean intensities of 6 individual samples
in each immunization group with the mean level of expression measured in mice given gavage buffer. Quantification of fluorescent DNA signals in
agarose gels was performed by use of the software Quantify1D (Advanced American Biotechnology).
vehicle by different mucosal routes by use of TTFC as antigen
[24, 42, 43]. Cell-wall mutants of this carrier that exhibited im-
proved antigen-delivery capacities have recently been described
[26]. We therefore used both the wt and the alr MD007 mutant
strains in intragastric immunization experiments. Our data pro-
vide evidence that the recombinant strains that we constructed
produced the antigen in microgram quantities in vitro. This in-
dicates that, at the time of administration, antigen doses equiv-
alent to those of purified rUreB/CT [5] were given to mice.
Recombinant bacteria recovered from feces of immunized mice
showed a preserved capacity to produce UreB, suggesting that
sustained delivery of antigen occurs in vivo. We demonstrated
that, although similar IgG and IgA antibody levels were obtained,
the MD007/pMEC142 strain promoted a more pronounced re-
duction in H. felis load after challenge than did its wt counterpart.
This was accompanied by a reduced expression of proinflam-
matory chemokines/cytokine involved in Helicobacter infection.
The wt L. plantarum NCIMB8826 strain did not exhibit intrin-
sic protective properties in mice challenged with H. felis, as was
demonstrated by the absence of an effect induced by the 8826/
pTG2247 control strain. However, it is worth mentioning that
probiotic-based interventions against H. pylori infections by use
of different species of LAB have shown partial beneficial effects
that deserve further examination [44, 45].
A variety of antigens have been produced in different LAB
strains, belonging mostly to the Lactococcus and Lactobacillus
genera [21]. Although seric or mucosal antibody responses have
been measured, protection studies against the targeted pathogen
were rarely performed or turned out to be unsuccessful [46, 47],
with the notable exception of protective immunity demonstrated
by use of the potent immunogen TTFC [48]. The ability of LAB
carriers to induce protective immune responses depends on suf-
ficient antigen delivery in vivo and might be limited by their
poor adjuvant properties. Optimization of LAB carriers requires
selecting or defining the most-suitable LAB vehicle, the mode of
antigen presentation (cytoplasmic, secreted, or cell-surface ex-
posed), and the immunization regimen (route, dose, or timing).
In this respect, a recombinant Lactococcus lactis strain producing
cytoplasmic UreB was shown to be unable to induce protection
against H. pylori in a mouse model [47]. Notably, the reported
experimental setting led to very weak antibody responses. The
authors concluded that the adjuvant effect of L. lactis was in-
sufficient to trigger robust immune responses when used to de-
liver a weak immunogen, yet poor persistence of the strain in
the GI tract might be considered too.
It is worth noting that, in mucosal immunization against
Helicobacter species, the recombinant alrMD007 mutant turned
out to be superior to CpG immunostimulatory oligodeoxynu-
cleotides used as adjuvant [49], although it did not perform as
well as CT. Our data fully corroborate the results obtained by
use of the potent TTFC antigen and, thus, mark the alrMD007
mutant as a substantially improved delivery system that is also
applicable to weak antigens. This likely results from enhanced
in vivo release of antigen or improved antigen presentation to
antigen-presenting cells; the 8826 and MD007 strains exhibit
very similar persistence capacity in the mouse GI tract (data
not shown). To the best of our knowledge, this is the first
demonstration of the successful induction of partial mucosal
protection against H. felis in mice by use of recombinant LAB
as live antigen carriers. Coexpression of immunoregulatory cy-
tokines [50, 51], combined with improved LAB vehicles, rep-
resents a valuable step toward further improvement of the pro-
totype strains described in the present study.
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